Sucampo Reports Third Quarter 2016 Financial Results
09 nov. 2016 06h30 HE
|
Sucampo Pharmaceuticals Inc
Results Driven by 73% Growth in Revenue GAAP EPS Growth of 12%; Adjusted EPS Growth of 58% Company Raises 2016 Guidance and Provides Preliminary 2017 Guidance Announces Settlement with Dr....
China Food and Drug Administration Accepts IND for Pivotal Study of AMITIZA(R) (lubiprostone)
15 juin 2015 16h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that the China Food and Drug Administration...
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Digestive Disease Week
15 mai 2015 16h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 15, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
Sucampo and Harbin Gloria Pharmaceuticals Enter Into Licensing Agreement for AMITIZA(R) (lubiprostone) in China
11 mai 2015 16h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 11, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global pharmaceutical company, today announced that it entered into an exclusive license,...
Sucampo Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2014 Earnings Call
18 févr. 2015 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Feb. 18, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will host its fourth quarter and...
AMITIZA(R) (lubiprostone) Mutual Recognition Procedure Closes With Recommendation for Approval in European Countries
30 janv. 2015 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Jan. 30, 2015 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced the successful completion of the European...
Sucampo Announces Acceptance of New Drug Submission for AMITIZA(R) (lubiprostone) by Health Canada
30 déc. 2014 17h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Dec. 30, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that Health Canada has accepted the...
Sucampo Announces Third Quarter 2014 Financial Results
06 nov. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
Strong Revenue and Sales Growth for AMITIZA
Raises 2014 Earnings Guidance, Excluding Special Items
CEO Peter Greenleaf to Provide Update on Significant Progress Against Strategic Plan...
Takeda and Sucampo Enter Into Global Licensing Agreement for AMITIZA(R) (lubiprostone)
21 oct. 2014 18h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., October 21, 2014 and OSAKA, Japan, October 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, and Takeda...
Sucampo Announces Extension of AMITIZA(R) (lubiprostone) License and Collaboration Agreement With Takeda
14 oct. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it signed on October 9, 2014 an...